Drug Profile
Research programme: anti-leukaemia antibody therapeutics - Leukemia Therapeutics
Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Leukemia Therapeutics
- Class Antibodies; Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Adult T-cell leukaemia-lymphoma; Hairy cell leukaemia
Most Recent Events
- 28 May 2022 No recent reports of development identified for research development in Acute-myeloid-leukaemia in USA
- 28 May 2022 No recent reports of development identified for research development in Adult T cell leukaemia-lymphoma in USA
- 28 May 2022 No recent reports of development identified for research development in Hairy-cell-leukaemia in USA